CLDX Share Price

Open 3.78 Change Price %
High 3.89 1 Day 0.01 0.27
Low 3.72 1 Week 0.20 5.63
Close 3.75 1 Month -0.42 -10.07
Volume 1570359 1 Year -11.53 -75.46
52 Week High 16.65
52 Week Low 2.85
CLDX Important Levels
Resistance 2 3.91
Resistance 1 3.84
Pivot 3.79
Support 1 3.66
Support 2 3.59
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

CLDX Technical Analysis 4
As on 9th Dec 2016 CLDX Share Price closed @ 3.75 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.80 & Sell for SHORT-TERM with Stoploss of 3.83 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLDX Target for December
1st Target up-side 4.99
2nd Target up-side 5.82
3rd Target up-side 6.65
1st Target down-side 2.63
2nd Target down-side 1.8
3rd Target down-side 0.97
CLDX Other Details
Segment EQ
Market Capital 363793952.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celldextherapeutics.com
CLDX Address
CLDX
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
United States
Phone: 908-200-7500
Fax: 908-454-1911
Interactive Technical Analysis Chart Celldex Therapeutics, Inc. ( CLDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Celldex Therapeutics, Inc.
CLDX Business Profile
Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.